... Jul 17
Recommendation based on positive results from the Phase 3 CheckMate -577 trial in which Opdivo doubled disease-free survival compared to placebo in the all-... Jun 25
Significantly improves progression-free Survival vs. Opdivo (nivolumab) in patients... May 22
The antibody is indicated for patients with previously untreated Metastatic or unresectable melanoma... Mar 27
Compugen Ltd expands collaboration agreement with Bristol Myers Squibb with phase 1b combination study of COM701 with opdivo C... Feb 22
... Jan 05
... Dec 23
Bristol Myers Squibb announced the approval of Opdivo for the treatment of adults with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma ... Nov 25
European Commission decision marks the first time a dual immunotherapy with limited chemotherapy is approved for patients with non-small cell lung cancer in the ... Nov 09
Results from CheckMate -9ER recently presented during a Presidential Symposium at the European Society for Medical Oncology Virtual Congress... Oct 19
Sumitomo Dainippon Pharma Oncology announces first patient dosed with TP-1454 in patients with advanced solid tumours ... Oct 10
US FDA approved for the first-line treatment of adults with malignant pleural mesothelioma that cannot be removed by surgery... Oct 05
Opdivo + Yervoy is the first new systemic therapy in over 15 years to be approved by the FDA ... Oct 03
City of Hope enters licensing agreement with Chimeric Therapeutics Limited to develop its pioneering chlorotoxin CAR T Cell therapy ... Sep 22
Compugen Ltd., a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today declared their 4th and full year report.... Feb 21
... Sep 13
First-line pembrolizumab monotherapy provides durable long-term overall survival benefit compared to chemotherapy, according to data presented today by Dr. M. Reck, Lung Clinic ... Sep 10
-Advertisements-
Wednesday, May 15, 2024
.jpeg)
